Wednesday, 3 July 2013

Questions (207)

Mary Lou McDonald


207. Deputy Mary Lou McDonald asked the Minister for Health further to Parliamentary Questions Nos. 901, 902 and 941 for 11 June 2013, if the Health Service Executive concluded its consideration of the Intermune offer in relation to the pricing of Pirfenidone; and if not, by what date will a decision be reached. [32314/13]

View answer

Written answers (Question to Health)

The HSE has completed the consideration of the pricing and reimbursement application for Pirfenidone (Esbriet). The pricing and reimbursement application and associated commercially confidential offer made by Intermune has been accepted.

The HSE has been in contact with Intermune (the market authorisation holder) and has confirmed that it will be in a position to commence reimbursement from 1st of August 2013, subject to Intermune being in a position to launch the product. The HSE expects that Intermune will be in a position to launch on the 1st of August. The administrative processes to allow reimbursement to happen are ongoing and will be completed over the next few weeks.